Halia Therapeutics is a clinical-stage biopharma company pioneering medicines that restore the body’s innate resilience. Founded on a genetic discovery in Utah linking reduced RAB10 expression to protection from Alzheimer’s, Halia targets the LRRK2→RAB10→NEK7→NLRP3 pathway. HT-4253, a LRRK2 inhibitor for Alzheimer’s, and HT-6184, a NEK7 modulator in Phase 2 for MDS and obesity, phenocopy this resilience, resolving inflammation to restore health.